Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Povidone-Iodine for COVID-19: real-time meta analysis of 20 studies
Covid Analysis, December 2022
https://c19early.org/pmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mohamed (RCT) 86% 0.14 [0.01-2.21] viral+ 0/5 3/5 Improvement, RR [CI] Treatment Control Choudhury (RCT) 88% 0.12 [0.03-0.50] death 2/303 17/303 Choudhury (RCT) 84% 0.16 [0.09-0.28] hosp. 12/303 77/303 Choudhury (RCT) 96% 0.04 [0.02-0.07] viral+ 8/303 213/303 Guenezan (RCT) 63% 0.37 [0.06-1.63] viral load 12 (n) 12 (n) Elzein (DB RCT) 89% 0.11 [0.01-1.00] viral load 25 (n) 9 (n) Short term viral Arefin (RCT) 79% 0.21 [0.08-0.54] viral+ 4/27 19/27 Short term viral Arefin (RCT) 89% 0.11 [0.03-0.41] viral+ 2/27 19/27 Short term viral Arefin (RCT) 53% 0.47 [0.26-0.85] viral+ 9/27 19/27 Short term viral Arefin (RCT) 80% 0.20 [0.09-0.44] viral+ 5/27 25/27 Short term viral Arefin (RCT) 64% 0.36 [0.21-0.62] viral+ 9/27 25/27 Short term viral Arefin (RCT) 74% 0.26 [0.19-0.37] viral+ 29/135 44/54 Short term viral Baxter (RCT) 65% 0.35 [0.01-8.27] hosp. 0/37 1/42 OT​1 Baxter (RCT) 57% 0.43 [0.20-0.94] no recov. 6/27 18/35 OT​1 Baxter (RCT) 37% 0.63 [0.19-2.05] transmission 4/37 6/35 OT​1 Pablo-Marcos 29% 0.71 [0.32-1.56] viral load 31 (n) 40 (n) Pablo-Marcos 9% 0.91 [0.20-4.16] viral load 31 (n) 40 (n) Sulistyani (SB RCT) 6% 0.94 [0.45-1.96] viral load 15 (n) 15 (n) Sulistyani (SB RCT) 11% 0.89 [0.42-1.88] viral load 15 (n) 15 (n) Elsersy (DB RCT) 91% 0.09 [0.01-1.62] hosp. 0/100 5/100 CT​2 Elsersy (DB RCT) 15% 0.85 [0.76-0.96] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 49% 0.51 [0.42-0.62] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 48% 0.52 [0.43-0.63] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 68% 0.32 [0.22-0.49] viral+ 21/100 65/100 CT​2 Elsersy (DB RCT) 90% 0.10 [0.01-0.77] viral+ 1/100 10/100 CT​2 Elsersy (DB RCT) 29% 0.71 [0.62-0.81] viral+ 70/100 99/100 CT​2 Elsersy (DB RCT) 92% 0.08 [0.05-0.14] transmission 12/194 173/227 CT​2 Elsersy (DB RCT) 94% 0.06 [0.03-0.12] transmission 8/194 157/227 CT​2 Sevinç Gül (RCT) 99% 0.01 [0.00-439] viral load 21 (n) 20 (n) Short term viral OT​1 Natto (RCT) 74% 0.26 [0.02-2.80] viral load 12 (n) 12 (n) Short term viral OT​1 Natto (RCT) 96% 0.04 [0.00-2.26] viral load 12 (n) 12 (n) Short term viral OT​1 Natto (RCT) 44% 0.56 [0.07-4.53] viral load 12 (n) 12 (n) Short term viral OT​1 Sirijatuphat 33% 0.67 [0.17-2.67] viral load 12 (n) 12 (n) Short term viral Sirijatuphat 88% 0.12 [0.02-0.94] viral load 12 (n) 12 (n) Short term viral Sirijatuphat 83% 0.17 [0.02-1.49] viral load 12 (n) 12 (n) Short term viral Karaaltin (RCT) 83% 0.17 [0.05-0.62] viral load 30 (n) 30 (n) Karaaltin (RCT) 86% 0.14 [0.05-0.46] viral load 30 (n) 30 (n) Karaaltin (RCT) 82% 0.18 [0.02-1.71] viral load 30 (n) 30 (n) Karaaltin (RCT) 91% 0.09 [0.03-0.30] viral load 30 (n) 30 (n) Matsuyama (RCT) 69% 0.31 [0.10-0.93] viral+ 4/139 13/140 Matsuyama (RCT) 38% 0.62 [0.42-0.92] viral+ 139 (n) 140 (n) Seneviratne (RCT) 33% 0.67 [0.50-0.91] viral load 4 (n) 2 (n) Short term viral Zarabanda (RCT) -27% 1.27 [0.26-6.28] no recov. 3/13 2/11 OT​1 Zarabanda (RCT) -50% 1.50 [0.31-7.30] no recov. 3/11 2/11 OT​1 Zarabanda (RCT) 0% 1.00 [0.19-5.24] viral+ 2/7 2/7 OT​1 Jamir (ICU) 57% 0.43 [0.27-0.69] death 39/163 62/103 ICU patients Ferrer (RCT) 34% 0.66 [0.02-19.0] viral load 9 (n) 12 (n) Short term viral Fantozzi (RCT) 31% 0.69 [0.39-1.21] viral+ 5/8 10/11 Short term viral OT​1 Fantozzi (RCT) 59% 0.41 [0.17-1.03] viral+ 3/8 10/11 Short term viral OT​1 Seet (CLUS. RCT) 45% 0.55 [0.38-0.80] symp. case 42/735 64/619 OT​1 Seet (CLUS. RCT) 31% 0.69 [0.52-0.92] cases 338/735 433/619 OT​1 Povidone-iodine COVID-19 outcomes c19early.org/p Dec 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors povidone-iodine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit